An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils
- Heinrich Heine University Düsseldorf, Germany
- University of Cambridge, United Kingdom
- RWTH Aachen University, Germany
- Technical University of Denmark, Denmark
Abstract
Removing or preventing the formation of α-synuclein aggregates is a plausible strategy against Parkinson's disease. To this end we have engineered the β-wrapin AS69 to bind monomeric α-synuclein with high affinity. In cultured cells, AS69 reduced the self-interaction of α-synuclein and the formation of visible α-synuclein aggregates. In flies, AS69 reduced α-synuclein aggregates and the locomotor deficit resulting from α-synuclein expression in neuronal cells. In biophysical experiments in vitro, AS69 highly sub-stoichiometrically inhibited both primary and autocatalytic secondary nucleation processes, even in the presence of a large excess of monomer. We present evidence that the AS69-α-synuclein complex, rather than the free AS69, is the inhibitory species responsible for sub-stoichiometric inhibition of secondary nucleation. These results represent a new paradigm that high affinity monomer binders can lead to strongly sub-stoichiometric inhibition of nucleation processes.
Data availability
- Numerical data represented in the graphs for cell culture and fly experiments will be made publicly available on osf.io as we did for previous publications.- The numerical data for the biophysical experiments will be made publicly available within the same repository on osf.io.- The raw images of the gels used in the publication will be made publicly available.All data have been deposited on osf.io ( https://osf.io/6n2gs/?view_only=7eb7024d8ecb460a817cd0ed35978339 ) and will be made available in the event of publication
Article and author information
Author details
Funding
Leverhulme Trust
- Alexander K Buell
Boehringer Ingelheim Fonds
- Patrick Flagmeier
Studienstiftung des Deutschen Volkes
- Patrick Flagmeier
Alexander von Humboldt-Stiftung
- Céline Galvagnion
H2020 European Research Council (726368)
- Céline Galvagnion
Parkinson's and Movement Disorder Foundation
- Alexander K Buell
European Commission (706551)
- Céline Galvagnion
Novo Nordisk Foundation
- Alexander K Buell
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2019, Agerschou et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 5,659
- views
-
- 865
- downloads
-
- 64
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Citations by DOI
-
- 64
- citations for umbrella DOI https://doi.org/10.7554/eLife.46112
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils
eLife 8:e46112.
https://doi.org/10.7554/eLife.46112
